CoChat
Sign Up
Cited by 175SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Open access
Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L, Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A, Kanji, Nasir, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Maallah, Mina, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Bawa, Tanveer, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C, Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Liu, Xinxue, Faust, Saul N, Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L, Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A, Kanji, Nasir, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Bawa, Tanveer, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Maallah, Mina, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C, Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Liu, Xinxue, Faust, Saul N, Riordan, Andrew, Ustianowski, Andrew, Rogers, Chris, Katechia, Kashyap, Cooper, Alison, Freedman, Andrew, Hughes, Rachel, Grundy, Lynne, Tudor Jones, Lona, Harrison, Elizabeth, Snashall, Emma, Mallon, Lewis, Burton, Katharine, Storton, Kim, Munusamy, Malathi, Tandy, Bridget, Egbo, Akamino, Cox, Stephen, Ahmed, Nabeela Nazir, Shenoy, Anil, Bousfield, Rachel, Wixted, Donna, Gutteridge, Helen, Mansfield, Becky, Herbert, Christopher, Murira, Jennifer, Calderwood, James, Barker, Dominique, Brandon, Jacqueline, Tulloch, Hayley, Colquhoun, Suzie, Thorp, Helen, Radford, Helen, Evans, Julie, Baker, Helena, Thorpe, Jeanette, Batham, Sally, Hailstone, Jessica, Phillips, Rachael, Kumar, Dileep, Westwell, Fran, Sturdy, Ann, Barcella, Lara, Soussi, Najwa, Mpelembue, Mushiya, Raj, Sreena, Sharma, Rajni, Corrah, Tumena, John, Laurence, Whittington, Ashley, Roche, Siobhan, Wagstaff, Lynda, Farrier, Adam, Bisnauthsing, Karen, Abeywickrama, Movin, Spence, Niamh, Packham, Alice, Serafimova, Teona, Aslam, Suahil, McGreevy, Caitlin, Borca, Alessandro, DeLosSantosDominguez, Pamela, Palmer, Emily, Broadhead, Samantha, Farooqi, Sadaf, Piper, Jo, Weighell, Rowena, Pickup, Lorinda, Shamtally, Djamila, Domingo, Jason, Kourampa, Evgenia, Hale, Colin, Gibney, Jennifer, Stackpoole, Michael, Rashid-Gardner, Zalina, Lyon, Rebecca, McDonnell, Chloe, Cole, Christine, Stewart, Anna, McMillan, Gillian, Savage, Mary, Beckett, Helen, Moorbey, Chantelle, Desai, Amisha, Brown, Claire, Naker, Kush, Gokani, Karishma, Trinham, Charlotte, Sabine, Charlette, Moore, Sophie, Hurdover, Steve, Justice, Edwin, Stone, Megan, Plested, Emma, Ferreira Da Silva, Carla, White, Rachel, Robinson, Hannah, Turnbull, Iain, Morshead, Gertraud, Drake-Brockman, Rachael, Smith, Catherine, Li, Grace, Kasanyinga, Mwila, Clutterbuck, Elizabeth A, Bibi, Sagida, Singh, Michael, Champaneri, Trishna, Irwin, Margaret, Khan, Mohammed, Kownacka, Alicia, Nabunjo, Martha, Osuji, Carol, Hladkiwskyj, John, Galvin, Dominic, Patel, Gita, Grierson, Jacques, Males, Samantha, Askoolam, Krishna, Barry, Joshua, Mouland, Johanna, Longhurst, Beverley, Moon, Maria, Giddins, Beth, Pereira Dias Alves, Carlota, Richmond, Leah, Minnis, Christine, Baryschpolec, Sonia, Elliott, Scott, Fox, Lauren, Graham, Victoria, Baker, Natalie, Godwin, Kerry, Buttigieg, Karen, Knight, Chanice, Brown, Phillip, Lall, Paminder, Shaik, Imam, Chiplin, Emily, Brunt, Emily, Leung, Stephanie, Allen, Lauren, Thomas, Steve, Fraser, Sara, Choi, Bea, Gouriet, Jade, Perkins, Jonathan, Gowland, Andrew, Macdonald, Jonathan, Seenan, John Paul, Starinskij, Igor, Seaton, Andrew, Peters, Erica, Singh, Stephen, Gardside, Ben, Bonnaud, Avril, Davies, Ceri, Gordon, Elizabeth, Keenan, Samantha, Hall, Jane, Wilkins, Suzanne, Tasker, Suzanne, James, Rob, Seath, Ingrid, Littlewood, Kelly, Newman, Joseph, Boubriak, Iryna, Suggitt, Debbie, Haydock, Helen, Bennett, Sara, Woodyatt, Wiesia, Hughes, Kerry, Bell, Judith, Coughlan, Tricia, van Welsenes, Donald, Kamal, Mohammed, Cooper, Chris, Tunstall, Simon, Ronan, Nicholas, Cutts, Rebecca, Dare, Tracey, Yim, Yee Ting Nicole, Whittley, Sarah, Hamal, Shama, Ricamara, Marivic, Adams, Kirsty, Baker, Holly, Driver, Kimberley, Turner, Nicola, Rawlins, Todd, Roy, Subarna, Merida-Morillas, Marta, Sakagami, Yukari, Andrews, Antonette, Goncalvescordeiro, Lillian, Stokes, Matthew, Ambihapathy, Wythehi, Spencer, Joanne, Parungao, Nina, Berry, Lisa, Cullinane, James, Presland, Laura, Ross Russell, Amy, Warren, Sarah, Baker, Jonathan, Oliver, Abigail, Buadi, Amanda, Lee, Kim, Haskell, Louise, Romani, Rossana, Bentley, Ian, Whitbred, Tim, Fowler, Simon, Gavin, John, Magee, Alan, Watson, Tara, Nightingale, Kari, Marius, Phedra, Summerton, Eloise, Locke, Emily, Honey, Thomas, Lingwood, Aidan, de la Haye, Anastasia, Elliott, Ryan Stephen, Underwood, Karen, King, Mikayala, Davies-Dear, Sharon, Horsfall, Emily, Chalwin, Olivia, Burton, Holly, Edwards, Christopher J, Welham, Benjamin, Appleby, Kim, Dineen, Emily, Garrahy, Sarah, Hall, Fran, Ladikou, Eleni, Mullan, Dee, Hansen, Daniel, Campbell, Marion, Dos Santos, Filipa, Lakeman, Nicki, Branney, Debbie, Vamplew, Luke, Hogan, Alison, Frankham, Jorden, Wiselka, Martin, Vail, Denny, Wenn, Victoria, Renals, Valerie, Ellis, Kate, Lewis-Taylor, Jessica, Habash-Bailey, Haniah, Magan, Javier, Hardy, Anna·2022·The Lancet Infectious Diseases
DOI 10.1016/s1473-3099(22)00271-7PMC PMC9084623
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19. METHODS: The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK. This sub-study enrolled participants who had received BNT162b2 (Pfizer-BioNTech) as their third dose in COV-BOOST and randomly assigned them (1:1) to receive a fourth dose of either BNT162b2 (30 μg in 0·30 mL; full dose) or mRNA-1273 (Moderna; 50 μg in 0·25 mL; half dose) via intramuscular injection into the upper arm. The computer-generated randomisation list was created by the study statisticians with random block sizes of two or four. Participants and all study staff not delivering the vaccines were masked to treatment allocation. The coprimary outcomes were safety and reactogenicity, and immunogenicity (anti-spike protein IgG titres by ELISA and cellular immune response by ELISpot). We compared immunogenicity at 28 days after the third dose versus 14 days after the fourth dose and at day 0 versus day 14 relative to the fourth dose. Safety and reactogenicity were assessed in the per-protocol population, which comprised all participants who received a fourth-dose booster regardless of their SARS-CoV-2 serostatus. Immunogenicity was primarily analysed in a modified intention-to-treat population comprising seronegative participants who had received a fourth-dose booster and had available endpoint data. This trial is registered with ISRCTN, 73765130, and is ongoing. FINDINGS: Between Jan 11 and Jan 25, 2022, 166 participants were screened, randomly assigned, and received either full-dose BNT162b2 (n=83) or half-dose mRNA-1273 (n=83) as a fourth dose. The median age of these participants was 70·1 years (IQR 51·6-77·5) and 86 (52%) of 166 participants were female and 80 (48%) were male. The median interval between the third and fourth doses was 208·5 days (IQR 203·3-214·8). Pain was the most common local solicited adverse event and fatigue was the most common systemic solicited adverse event after BNT162b2 or mRNA-1273 booster doses. None of three serious adverse events reported after a fourth dose with BNT162b2 were related to the study vaccine. In the BNT162b2 group, geometric mean anti-spike protein IgG concentration at day 28 after the third dose was 23 325 ELISA laboratory units (ELU)/mL (95% CI 20 030-27 162), which increased to 37 460 ELU/mL (31 996-43 857) at day 14 after the fourth dose, representing a significant fold change (geometric mean 1·59, 95% CI 1·41-1·78). There was a significant increase in geometric mean anti-spike protein IgG concentration from 28 days after the third dose (25 317 ELU/mL, 95% CI 20 996-30 528) to 14 days after a fourth dose of mRNA-1273 (54 936 ELU/mL, 46 826-64 452), with a geometric mean fold change of 2·19 (1·90-2·52). The fold changes in anti-spike protein IgG titres from before (day 0) to after (day 14) the fourth dose were 12·19 (95% CI 10·37-14·32) and 15·90 (12·92-19·58) in the BNT162b2 and mRNA-1273 groups, respectively. T-cell responses were also boosted after the fourth dose (eg, the fold changes for the wild-type variant from before to after the fourth dose were 7·32 [95% CI 3·24-16·54] in the BNT162b2 group and 6·22 [3·90-9·92] in the mRNA-1273 group). INTERPRETATION: Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and boost cellular and humoral immunity. Peak responses after the fourth dose were similar to, and possibly better than, peak responses after the third dose. FUNDING: UK Vaccine Task Force and National Institute for Health Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(22)00271-7

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile *The full dose of BNT162b2 was 30 μg and the half dose of mRNA-1273 was 50 μg.
Figure 1 Trial profile *The full dose of BNT162b2 was 30 μg and the half dose of mRNA-1273 was 50 μg.CC BY · PubMed Central
Figure 2 Solicited adverse events within 7 days following fourth-dose vaccination in participants who received a study vaccine (A) Severe (grade 3–4) local and systemic adverse events. (B) Moderate or severe (grade 2–4) local and systemic adverse events. For each solicited adverse event, the highest severity within the first 7 days after fourth-dose vaccination at an individual level was used to draw the plot.
Figure 2 Solicited adverse events within 7 days following fourth-dose vaccination in participants who received a study vaccine (A) Severe (grade 3–4) local and systemic adverse events. (B) Moderate or severe (grade 2–4) local and systemic adverse events. For each solicited adverse event, the highest severity within the first 7 days after fourth-dose vaccination at an individual level was used to draw the plot.CC BY · PubMed Central
Figure 3 Kinetics of immunogenicity in seronegative participants (A) Anti-spike protein IgG titres. (B) Cellular response. Boxplots represent the median and 25th and 75th percentiles. Each data point is one participant. Solid lines connect samples from the same participant at multiple timepoints. The dashed line represents the lower limit of detection by the ELISpot assay. 3D0=pre-third dose. 3D28=28 days after the third dose. 4D0=pre-fourth dose. 4D14=14 days after the fourth dose. ELU=ELISA laboratory units. PBMCs=peripheral blood mononuclear cells. SFCs=spot forming cells.
Figure 3 Kinetics of immunogenicity in seronegative participants (A) Anti-spike protein IgG titres. (B) Cellular response. Boxplots represent the median and 25th and 75th percentiles. Each data point is one participant. Solid lines connect samples from the same participant at multiple timepoints. The dashed line represents the lower limit of detection by the ELISpot assay. 3D0=pre-third dose. 3D28=28 days after the third dose. 4D0=pre-fourth dose. 4D14=14 days after the fourth dose. ELU=ELISA laboratory units. PBMCs=peripheral blood mononuclear cells. SFCs=spot forming cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 1

  1. Andrews, 2022, COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N Engl J Med, 386, 1532, 10.1056/NEJMoa2119451 · DOI · Paper page

Cited by

Sorted by citations

Items 101–174 of 174

Related

See all

Metadata

Authors
Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kanji, N., Libri, V., Llewelyn, M. J., McGregor, A. C., Maallah, M., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Bawa, T., Saralaya, D., Sharma, S., Sheridan, R., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Snape, M. D., Liu, X., Faust, S. N., Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kanji, N., Libri, V., Llewelyn, M. J., McGregor, A. C., Minassian, A. M., Moore, P., Mughal, M., Mujadidi, Y. F., Holliday, K., Osanlou, O., Osanlou, R., Owens, D. R., Pacurar, M., Palfreeman, A., Pan, D., Rampling, T., Regan, K., Saich, S., Bawa, T., Saralaya, D., Sharma, S., Sheridan, R., Maallah, M., Thomson, E. C., Todd, S., Twelves, C., Read, R. C., Charlton, S., Hallis, B., Ramsay, M., Andrews, N., Lambe, T., Nguyen-Van-Tam, J. S., Snape, M. D., Liu, X., Faust, S. N., Riordan, A., Ustianowski, A., Rogers, C., Katechia, K., Cooper, A., Freedman, A., Hughes, R., Grundy, L., Tudor Jones, L., Harrison, E., Snashall, E., Mallon, L., Burton, K., Storton, K., Munusamy, M., Tandy, B., Egbo, A., Cox, S., Ahmed, N. N., Shenoy, A., Bousfield, R., Wixted, D., Gutteridge, H., Mansfield, B., Herbert, C., Murira, J., Calderwood, J., Barker, D., Brandon, J., Tulloch, H., Colquhoun, S., Thorp, H., Radford, H., Evans, J., Baker, H., Thorpe, J., Batham, S., Hailstone, J., Phillips, R., Kumar, D., Westwell, F., Sturdy, A., Barcella, L., Soussi, N., Mpelembue, M., Raj, S., Sharma, R., Corrah, T., John, L., Whittington, A., Roche, S., Wagstaff, L., Farrier, A., Bisnauthsing, K., Abeywickrama, M., Spence, N., Packham, A., Serafimova, T., Aslam, S., McGreevy, C., Borca, A., DeLosSantosDominguez, P., Palmer, E., Broadhead, S., Farooqi, S., Piper, J., Weighell, R., Pickup, L., Shamtally, D., Domingo, J., Kourampa, E., Hale, C., Gibney, J., Stackpoole, M., Rashid-Gardner, Z., Lyon, R., McDonnell, C., Cole, C., Stewart, A., McMillan, G., Savage, M., Beckett, H., Moorbey, C., Desai, A., Brown, C., Naker, K., Gokani, K., Trinham, C., Sabine, C., Moore, S., Hurdover, S., Justice, E., Stone, M., Plested, E., Ferreira Da Silva, C., White, R., Robinson, H., Turnbull, I., Morshead, G., Drake-Brockman, R., Smith, C., Li, G., Kasanyinga, M., Clutterbuck, E. A., Bibi, S., Singh, M., Champaneri, T., Irwin, M., Khan, M., Kownacka, A., Nabunjo, M., Osuji, C., Hladkiwskyj, J., Galvin, D., Patel, G., Grierson, J., Males, S., Askoolam, K., Barry, J., Mouland, J., Longhurst, B., Moon, M., Giddins, B., Pereira Dias Alves, C., Richmond, L., Minnis, C., Baryschpolec, S., Elliott, S., Fox, L., Graham, V., Baker, N., Godwin, K., Buttigieg, K., Knight, C., Brown, P., Lall, P., Shaik, I., Chiplin, E., Brunt, E., Leung, S., Allen, L., Thomas, S., Fraser, S., Choi, B., Gouriet, J., Perkins, J., Gowland, A., Macdonald, J., Seenan, J. P., Starinskij, I., Seaton, A., Peters, E., Singh, S., Gardside, B., Bonnaud, A., Davies, C., Gordon, E., Keenan, S., Hall, J., Wilkins, S., Tasker, S., James, R., Seath, I., Littlewood, K., Newman, J., Boubriak, I., Suggitt, D., Haydock, H., Bennett, S., Woodyatt, W., Hughes, K., Bell, J., Coughlan, T., van Welsenes, D., Kamal, M., Cooper, C., Tunstall, S., Ronan, N., Cutts, R., Dare, T., Yim, Y. T. N., Whittley, S., Hamal, S., Ricamara, M., Adams, K., Baker, H., Driver, K., Turner, N., Rawlins, T., Roy, S., Merida-Morillas, M., Sakagami, Y., Andrews, A., Goncalvescordeiro, L., Stokes, M., Ambihapathy, W., Spencer, J., Parungao, N., Berry, L., Cullinane, J., Presland, L., Ross Russell, A., Warren, S., Baker, J., Oliver, A., Buadi, A., Lee, K., Haskell, L., Romani, R., Bentley, I., Whitbred, T., Fowler, S., Gavin, J., Magee, A., Watson, T., Nightingale, K., Marius, P., Summerton, E., Locke, E., Honey, T., Lingwood, A., de la Haye, A., Elliott, R. S., Underwood, K., King, M., Davies-Dear, S., Horsfall, E., Chalwin, O., Burton, H., Edwards, C. J., Welham, B., Appleby, K., Dineen, E., Garrahy, S., Hall, F., Ladikou, E., Mullan, D., Hansen, D., Campbell, M., Dos Santos, F., Lakeman, N., Branney, D., Vamplew, L., Hogan, A., Frankham, J., Wiselka, M., Vail, D., Wenn, V., Renals, V., Ellis, K., Lewis-Taylor, J., Habash-Bailey, H., Magan, J., & Hardy, A.
Affiliations
  • UK Health Security Agency (GB)
  • University of Leeds (GB)
  • NHS Greater Glasgow and Clyde (GB)
  • University Hospital Southampton NHS Foundation Trust (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • St Thomas' Hospital (GB)
  • University Hospitals Sussex NHS Foundation Trust (GB)
  • Bradford Teaching Hospitals NHS Foundation Trust (GB)
  • University of Nottingham (GB)
  • University of Oxford (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Imperial College London (GB)
  • Royal Devon & Exeter NHS Foundation Trust (GB)
  • University of Leicester (GB)
  • Broadgreen Hospital (GB)
ORCID
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2022-08
Volume
22
Issue
8
Pages
1131-1141
ISSN
1473-3099 (ISSN-L)
DOI
10.1016/s1473-3099(22)00271-7
PMC
PMC9084623
OpenAlex
W4229458272
Cited by
175
References
14
Citations by year
2026: 13 · 2025: 23 · 2024: 44 · 2023: 62 · 2022: 33
FWCI
19.80
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by)
  • Bangor University Research Portal (Bangor University) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • National Institute for Health and Care Research
  • Public Health England
  • Wellcome Trust (210755/Z/18/Z)
  • University Hospital Southampton NHS Foundation Trust (BNT162b2)
  • Government of the United Kingdom
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 vaccines, BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 vaccine, immunogenicity, reactogenicity, vaccine safety, anti-spike IgG, cell-mediated immunity, SARS-CoV-2
MeSH terms
Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, ChAdOx1 nCoV-19, Aged, Antibodies, Viral, Female, Humans, Immunoglobulin G, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review